

Amendment to the Specification:

Please insert the following paragraph at the beginning on page 1 of the specification:

-- This application is a divisional of U.S. Patent Application Serial No. 08/860,232 (filed on June 13, 1997, now abandoned), which is a national phase entry of PCT/US95/16415, (filed on December 14, 1995), which claims priority to U.S. Patent Application Serial No. 08/355,558 (filed on December 14, 1994, now abandoned).--

Please insert the following Abstract at the end of the specification:

- ABSTRACT OF THE DISCLOSURE

The present invention relates to methods and compositions of activating cytotoxic T lymphocytes (CTLs) in vivo with specificity for particular antigenic peptides, and to methods and compositions of using activated CTLs in vivo for the treatment of a variety of disease conditions. In some preferred embodiments, the invention provides methods of employing a polypeptide of the amino acid sequence VMAGVGSPYV to specifically activating CTLs in subjects having a breast cancer overexpressing a Her-2/Neu protein, and methods of using the polypeptide to treat such subjects. --